Refine
Has Fulltext
- yes (129)
Is part of the Bibliography
- yes (129) (remove)
Year of publication
Document Type
- Journal article (72)
- Doctoral Thesis (56)
- Other (1)
Keywords
- ADHD (16)
- ADHS (12)
- children (10)
- Aufmerksamkeitsdefizit-Syndrom (6)
- adolescents (6)
- methylphenidate (6)
- Anorexia nervosa (5)
- Methylphenidat (5)
- adolescence (5)
- therapeutic drug monitoring (5)
- Kind (4)
- Kinder- und Jugendpsychiatrie (4)
- NSSI (4)
- brain (4)
- eating disorders (4)
- fear generalization (4)
- mental health (4)
- Angst (3)
- Children (3)
- Furchtgeneralisierung (3)
- Jugend (3)
- Kinder (3)
- Kinder und Jugendliche (3)
- Komorbidität (3)
- RCT (3)
- Schizophrenie (3)
- Serotonin (3)
- Substantia nigra (3)
- anorexia nervosa (3)
- brain development (3)
- emotion regulation (3)
- pharmacovigilance (3)
- Angsterkrankungen (2)
- Angststörung (2)
- Arzneimittelüberwachung (2)
- Aufmerksamkeits-Defizit-Syndrom (2)
- Aufmerksamkeitsprozesse (2)
- Autismus-Spektrum-Störung (2)
- Brain-derived neurotrophic factor (2)
- COMT (2)
- Comorbidity (2)
- EEG (2)
- Early-onset (2)
- Elektroencephalogramm (2)
- Familienuntersuchung (2)
- Family-Investigation (2)
- Furcht (2)
- Furchtkonditionierung (2)
- GAD1 (2)
- Jugendliche (2)
- Kinderpsychiatrie (2)
- Komorbiditäten (2)
- OCD (2)
- PARK2 (2)
- Parkinson’s disease (2)
- Patientenzufriedenheit (2)
- Pharmakotherapie (2)
- Prävention (2)
- Psychische Störung (2)
- Qualitätssicherung (2)
- Satisfaction (2)
- TCS (2)
- Therapeutisches Drug Monitoring (2)
- Tourette syndrome (2)
- Transkranielle Sonographie (2)
- Transkranieller Ultraschall (2)
- Ultraschalldiagnostik (2)
- Zwangsstörung (2)
- anxiety disorders (2)
- attention deficit/hyperactivity disorder (2)
- attention-deficit/hyperactivity disorder (ADHD) (2)
- autism spectrum disorder (2)
- biomarkers (2)
- brain derived neurotrophic factor (2)
- brain disorders (2)
- case report (2)
- coercive measures (2)
- comorbidity (2)
- development (2)
- dopamine (2)
- dyslexia (2)
- employee stress (2)
- event-related potentials (2)
- fMRI (2)
- fear conditioning (2)
- hiPSC (2)
- longitudinal study (2)
- nervous system (2)
- norepinephrine (2)
- outcome (2)
- paediatrics (2)
- parents (2)
- prevention (2)
- prosocial behavior (2)
- proteomics (2)
- psychiatric disorders (2)
- quality assurance (2)
- residential institutions (2)
- serum concentration (2)
- substantia nigra pars compacta (2)
- universal prevention (2)
- working memory (2)
- 1p36 deletion syndrome (1)
- 21q22.2-q22.3 (1)
- 22q11 (1)
- 22q11.2 deletion syndrome (1)
- 22q11.2- Deletionssyndrom (1)
- 5-HTTLPR (1)
- ADHDS (1)
- AKI (1)
- Adolescence (1)
- Adoleszenz (1)
- Altersunterschied (1)
- Amphetamin (1)
- Angst als Eigenschaft (1)
- Angstintensität (1)
- Angstsensitivität (1)
- Angststörungen (1)
- Animal model (1)
- Anorexia nervosa in childhood (1)
- Anorexia nervosa treatment satisfaction (1)
- Antwortinhibition (1)
- Anxiety (1)
- Arbeitsbelastung (1)
- Assoziationsstudie (1)
- Attention-deficit hyperactivity disorder (1)
- Attention-deficit/hyperactivity disorder (1)
- Attentional Avoidance (1)
- Attentional Bias (1)
- Attentional bias (1)
- Aufklärung (1)
- Aufklärungsgespräch (1)
- Aufmerksamkeitsdefitit-/ Hyperaktivitätsstörung (1)
- Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörung (1)
- Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (1)
- Aversive tension (1)
- BDNF (1)
- BMI (1)
- Behandlung (1)
- Behandlungszufriedenheit kindlicher Patienten mit Anorexia nervosa nach stationärem Klinikaufenthalt (1)
- Belastung Eltern (1)
- Benennungsgeschwindigkeit (1)
- Big Five (1)
- Biomarker (1)
- Biomarkers (1)
- Blutspiegel (1)
- Body Image Disturbance (1)
- Braak (1)
- Bruxismus (1)
- CDH13 (1)
- CNS imaging (1)
- CNV (1)
- CNVs (1)
- COVID-19 (1)
- CPT (1)
- Central nervous system (1)
- Child (1)
- Childhood (1)
- Clinical Genetics (1)
- Clozapin (1)
- Clozapin/clozapine (1)
- Cognitive Behavioral Analysis System of Psychotherapy (1)
- Comorbidity survey replication (1)
- Connexin (1)
- Continous performance test (1)
- Continous-Performance-Test (1)
- Continuous Performance Test (1)
- Conversion (1)
- D5 (DRD4, DRD5) (1)
- DBT (1)
- DS 22q11.2 (1)
- DSM-IV Subtyp (1)
- DSM-IV Subtype (1)
- DSM-IV disorders (1)
- De-novo (1)
- Deletionssyndrom (1)
- Depression (1)
- DiGeorge-Syndrom (1)
- Discrimination (1)
- Disease progression (1)
- Disease-modifying therapies (1)
- Diskrimination (1)
- Dissociation (1)
- Dissoziation (1)
- Distress (1)
- Dopamin Agonist (1)
- Dopamine (1)
- Drug development (1)
- Dyslexia (1)
- EPMS (1)
- ERP (1)
- ESCAlife (1)
- Eating Disorders (1)
- Eating disorder (1)
- Ecological momentary assessment (1)
- Eisen (1)
- Elterliche Stressbelastung (1)
- Eltern ADHS (1)
- Elterntraining (1)
- Emotion regulation (1)
- Enrichment analysis (1)
- Entwicklung (1)
- Ereigniskorrelierte Potentiale (1)
- Erratum (1)
- Essstörungen (1)
- Estrogene (1)
- Extrapyramidales System (1)
- Eßstörungen (1)
- FIQ (1)
- FOXP2 (1)
- Fear (1)
- Fear generalization (1)
- Fgf-signalling (1)
- Fibromyalgia (1)
- Follow-up (1)
- Fragebogen (1)
- Furchtentwicklung (1)
- GABA (1)
- GFAP (1)
- GRM8 (1)
- GWAS (1)
- Gedächtnis (1)
- Gedächtnisspanne (1)
- Gehirn (1)
- Geistige Behinderung (1)
- Genetic etiology (1)
- Genpolymophismen (1)
- Geruchsdiskrimination (1)
- Geruchsidentifikation (1)
- Geruchsschwelle (1)
- Geruchssinn (1)
- Geschlechter (1)
- Gesundheitsbeeinträchtigung (1)
- Gewalt (1)
- Guanfacin (1)
- Heimeinrichtungen (1)
- Herzfrequenzvariabilität (1)
- Hurst Exponent (1)
- Hyperactivity (1)
- Hypothalamus (1)
- Hysteria (1)
- Hysterie (1)
- Immunsuppression (1)
- Impulsivität (1)
- Informed consent (1)
- Internalisierende Störung (1)
- Interview (1)
- Jugendpsychiatrie (1)
- Juvenile Psychose (1)
- K-SADS (1)
- KDIGO (1)
- Kinder und Jugendliche/children and adolescents (1)
- Kinderschutz (1)
- Kindesalter (1)
- Kindheit und Jugend (1)
- Kleinkern (1)
- Klinisches Experiment (1)
- Knochendichte (1)
- Knochendichteverlauf (1)
- Konditionierung (1)
- Konversion (1)
- Körperschemastörung (1)
- LRS (1)
- Lebenslauf (1)
- Lese-Rechtschreibschwäche (1)
- Locomotor activity (1)
- Längsschnittstudie (1)
- Längsschnittuntersuchung (1)
- Medical students (1)
- Medicine (1)
- Medikation (1)
- Medizinisches Aufklärungsgespräch (1)
- Metaanalyse (1)
- Metaanalysis (1)
- Mikrodeletionssyndrom (1)
- Mikrodeletionssyndrom 22q11 (1)
- Mindfulness (1)
- Missbrauch (1)
- Mitarbeiterbelastung (1)
- Motorische Fertigkeiten (1)
- Motorische Fähigkeit (1)
- Mutationsanalyse (1)
- NGA (1)
- Neuromelanin (1)
- Neuropeptid Y (1)
- Neuroprotection (1)
- Nierentransplantion (1)
- Olanzapin (1)
- Olanzapin/olanzapine (1)
- Olfaction (1)
- Oral Fluid (1)
- Parent–Child Interaction Therapy (PCIT) (1)
- Parkinson (1)
- Parkinson's disease (1)
- Parkinson-Krankheit (1)
- Peripheral expression (1)
- Periphere Expression (1)
- Pharmakovigilanz (1)
- Prevalence (1)
- Psychiatrischer Notfall (1)
- Psychopharmakotherapie (1)
- Riechen (1)
- Risperidon (1)
- Ropinirol (1)
- SNP (1)
- STBS (1)
- Scale (1)
- Schlafbruxismus (1)
- Sekundärkrankheit (1)
- Serotonerges System (1)
- Smartphones (1)
- Speichel (1)
- Stimulanz (1)
- Stimulanzien (1)
- Stress (1)
- Stress prevention (1)
- Störung des Sozialverhaltens (1)
- Substantia Nigra - Echogenität (1)
- Subtypen (1)
- Suchrate (1)
- Surrogate endpoints (1)
- TDM (1)
- TIC disorder (1)
- TIC disorders (1)
- Therapeutic Drug Monitoring (1)
- Therapeutisches Drug Monitoring/therapeutic drug monitoring (1)
- Therapy (1)
- Therpeutisches Drug Monitoring (1)
- Thigmotaxis (1)
- Transplantation (1)
- Transplantatüberleben (1)
- Trios (1)
- Tyrosinkinase (1)
- Tyrosinkinase Connexin (1)
- VAL66MET polymorphism (1)
- VBM (1)
- VIGALL (1)
- Verhaltensauffälligkeiten (1)
- Verhaltensstörung (1)
- Verhaltenstherapie (1)
- Vigilanz (1)
- Waiting Impulsivity (1)
- Zebrafish (1)
- Zufriedenheit (1)
- Zwangsstörungen (1)
- Zweikomponentensystem <Molekularbiologie> (1)
- actigraphy (1)
- adhd (1)
- adolescence anorexia nervosa (1)
- adult attention deficit/hyperactivity disorder (1)
- adult development (1)
- adult neurogenesis (1)
- adult treatment (1)
- adverse drug reactions (1)
- adverse effects (1)
- adversity (1)
- affective disorders (1)
- agreeableness (1)
- allostatic load (1)
- amenorrhea (1)
- analgesic medication (1)
- anticipatory mechanisms (1)
- anxiety (1)
- anxiety intensity (1)
- anxiety sensitivity (1)
- artifacts (1)
- association (1)
- association study (1)
- atention deficit order (1)
- attention deficit hyperactivity disorder (1)
- attention deficit hyperactivity disorder (ADHD) (1)
- attention deficit/hyperactivity disorder (ADHD) (1)
- attention-deficit/hyperactivity disorder (1)
- attentional processes (1)
- auditory discrimination (1)
- autism (1)
- autism spectrum disorder (ASD) (1)
- autoantibodies (1)
- basal ganglia (1)
- behavior problems (1)
- behaviour problems (1)
- behaviour therapy (1)
- berufliche Einschränkungen (1)
- biomarker (1)
- bipolar disorder (1)
- body mass index (1)
- bone density (1)
- bone-mineral density (1)
- breastfeeding (1)
- cancer (1)
- cardiac surgery (1)
- catecholamines (1)
- caudate nucleus (1)
- challenging behavior (1)
- challenging behaviours (1)
- changes in bone density (1)
- child and adolescent (1)
- child and adolescent psychiatry (1)
- child behavior (1)
- child memory (1)
- childhood maltreatment (1)
- children/adults (1)
- chromosome 21 (1)
- chronotype (1)
- classical conditioning (1)
- classification (1)
- clinical characteristics (1)
- clinical study (1)
- clinical trial (1)
- common SNPS (1)
- comparative genomics (1)
- complex diseases (1)
- computational modeling (1)
- congenital heart-deffects (1)
- contingent negative-variation (1)
- continuous performance task (CPT) (1)
- continuous performance test (1)
- continuous performance-test (1)
- coping strategies (1)
- copy-number variation (1)
- correlate (1)
- cytogenetic effects (1)
- data quality (1)
- deficit hyperactivity disorder (1)
- deficit-hyperactivity disorder (1)
- deletionsyndrom (1)
- dementia with Lewy bodies (1)
- dental development in children (1)
- depression (1)
- depressive symptoms (1)
- depressiveness (1)
- developmental disabilities (1)
- developmental dyscalculia (1)
- developmental dyslexia (1)
- digital phenotyping (1)
- disability (1)
- discrimination training (1)
- disease modelling (1)
- disease progression (1)
- disease-modifying therapies (1)
- disorders (1)
- distal deletion (1)
- dopamine agonist (1)
- dopamine receptor D4 (1)
- dopamine transporter (DAT) (1)
- dopaminergics (1)
- doublecortine-like (1)
- drug development (1)
- drug safety (1)
- dual guidance (1)
- dyscalculia (1)
- early-onset (1)
- ecological momentary assessment (1)
- efficacy (1)
- electroencephalography (1)
- electroencephalography (EEG) (1)
- emotional dysregulation (1)
- emotional paradigm (1)
- emotionales Paradigma (1)
- endophenotype (1)
- ereigniskorrelierte Potentiale (1)
- excitatory/inhibitory imbalance (1)
- executive functions (1)
- expression (1)
- family (1)
- family relations (1)
- fear extinction (1)
- fear-relevant training (1)
- feedback (1)
- fibromyalgia syndrome (1)
- freiheitsentziehende Maßnahmen (1)
- frontal cortex (1)
- functional magnetic resonance imaging (1)
- gender (1)
- genes (1)
- genome-wide association (1)
- genomic imaging (1)
- gilles (1)
- girls (1)
- glucose transporter (1)
- guidelines & recommendations (1)
- haplotypes (1)
- health status (1)
- herausforderndes Verhalten (1)
- hierarchical modeling (1)
- hippocampus (1)
- iPSC (1)
- identification (1)
- immunosuppression (1)
- impulse control disorders (1)
- inattention/hyperactivity (1)
- inattentive (1)
- increases (1)
- individual workload (1)
- individualised modular treatment programme (1)
- intellectual disabilities (1)
- intellectual disability (1)
- intelligence (1)
- intra-individual variability (IIV) (1)
- inventory (1)
- kinase (1)
- kindliche Zahnentwicklung (1)
- klinische Studie (1)
- longitudinal studies (1)
- mRNA expression (1)
- maternal stress (1)
- mathematics (1)
- maturation (1)
- medication (1)
- melatonin (1)
- memory (1)
- memory-span (1)
- menarche (1)
- menstrual recovery (1)
- mental disorders (1)
- meta-analysis (1)
- metabotropic glutamate (mGlu) receptor (1)
- micronucleus assay (1)
- mindfulness (1)
- minimum reporting standards (1)
- mismatch (1)
- mismatch negativity mmn (1)
- missing heritability (1)
- mitochondria (1)
- mitochondrial pathology (1)
- mitochondrial translation (1)
- mobile crowdsensing (1)
- mobile health (1)
- molecular neuroscience (1)
- moral balancing (1)
- mothers (1)
- motor preparation (1)
- multicenter study (1)
- multi‑center cohort study (1)
- mutagenicity (1)
- naming-speed (1)
- nephrotransplantation (1)
- neurodegeneration (1)
- neurodevelopment (1)
- neurogenesis (1)
- neuromelanin granules (1)
- neuroprotection (1)
- neuropsychiatric disorders (1)
- non-suicidal self-injury (1)
- nonsuicidal self-injury (NSSI) (1)
- noradrenaline (1)
- novelty detection (1)
- nucleus accumbens (1)
- objective assessment (1)
- obsessive-compulsive disorder (1)
- ocd (1)
- off label use (1)
- older adults (1)
- olfactory bulb neurogenesis (1)
- oppositional defiant disorder (1)
- oppositional-defiant disorder (1)
- ovarian function (1)
- parent training (1)
- parent-child interaction therapy (PCIT) (1)
- parent-child relationship (1)
- parental perception (1)
- parental stress (1)
- patient satisfaction (1)
- periodische Katatonie (1)
- peripheral expression (1)
- peripheral nerve involvement (1)
- periphere Expression Brain-derived neurotrophic factor (1)
- pharmacokinetics (1)
- pharmacotherapy (1)
- precursor symptoms (1)
- prelevance (1)
- preterm children (1)
- prevalence (1)
- probabilistic reversal learning (1)
- probiotic prophylaxis (1)
- processing deficits (1)
- prosocial (1)
- prosociality (1)
- protective factors (1)
- psychiatric comorbidity (1)
- psychiatric emergencies (1)
- psychische Belastung (1)
- psychological distress (1)
- psychopathology (1)
- psychopharmacotherapy (1)
- psychosis (1)
- psychotropic drugs (1)
- quantitative trait (1)
- rare diseases (1)
- reaction time (1)
- reading disability (1)
- recovery (1)
- reinforcement learning (1)
- reliability (1)
- renal (1)
- research errors (1)
- resilience (1)
- response-inhibition (1)
- responsivity (1)
- resumption of menses (1)
- return (1)
- review (1)
- risperidone (1)
- ropinirole (1)
- satisfaction with life (1)
- schizophrenia (1)
- schizophrenie (1)
- school (1)
- school-based prevention (1)
- schoolchildren (1)
- search-rate (1)
- selective mutism (1)
- self-injury (1)
- self-regulation (1)
- selfcompassion (1)
- serotonin (1)
- short-term methylphenidate brain (1)
- single photon emission computed tomography (SPECT) (1)
- skin conductance (1)
- sleep (1)
- sleep bruxism (1)
- slow cortical potentials (1)
- social influence (1)
- social recognition (1)
- speech perception (1)
- stem cells (1)
- stimulant (1)
- strength and difficulties (1)
- stress (1)
- stress granules (1)
- stress reduction (1)
- stressful life events (1)
- striatum (1)
- study (1)
- subtypes (1)
- subventricular zone (1)
- suicidality (1)
- sulcal morphology (1)
- supplements (1)
- support vector machines (1)
- surrogate endpoints (1)
- susceptibility gene (1)
- synaptosomes (1)
- syndrome (1)
- target weight (1)
- telephone-assisted self-help (1)
- tetrahydroisoquinoline derivates (1)
- third-wave psychotherapy (1)
- tiapride (1)
- tic disorders (1)
- tics (1)
- transcranial sonography (1)
- transcutaneous auricular vagus nerve stimulation (1)
- transcutaneous cervical vagus nerve stimulation (1)
- transcutaneous vagus nerve stimulation (1)
- transplantation (1)
- transporter gene SLC2A3 (1)
- treatment (1)
- triads (1)
- tumor-suppressor gene (1)
- unerwünschte Arzneimittelwirkungen (1)
- ventricular zone (1)
- vitamin D (1)
- weight gain (1)
- Östrogene (1)
- Übergewicht (1)
Institute
- Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (129) (remove)
Sonstige beteiligte Institutionen
The cell—cell signaling gene CDH13 is associated with a wide spectrum of neuropsychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD), autism, and major depression. CDH13 regulates axonal outgrowth and synapse formation, substantiating its relevance for neurodevelopmental processes. Several studies support the influence of CDH13 on personality traits, behavior, and executive functions. However, evidence for functional effects of common gene variation in the CDH13 gene in humans is sparse. Therefore, we tested for association of a functional intronic CDH13 SNP rs2199430 with ADHD in a sample of 998 adult patients and 884 healthy controls. The Big Five personality traits were assessed by the NEO-PI-R questionnaire. Assuming that altered neural correlates of working memory and cognitive response inhibition show genotype-dependent alterations, task performance and electroencephalographic event-related potentials were measured by n-back and continuous performance (Go/NoGo) tasks. The rs2199430 genotype was not associated with adult ADHD on the categorical diagnosis level. However, rs2199430 was significantly associated with agreeableness, with minor G allele homozygotes scoring lower than A allele carriers. Whereas task performance was not affected by genotype, a significant heterosis effect limited to the ADHD group was identified for the n-back task. Heterozygotes (AG) exhibited significantly higher N200 amplitudes during both the 1-back and 2-back condition in the central electrode position Cz. Consequently, the common genetic variation of CDH13 is associated with personality traits and impacts neural processing during working memory tasks. Thus, CDH13 might contribute to symptomatic core dysfunctions of social and cognitive impairment in ADHD.
The ability to perform mathematical tasks is required in everyday life. Although heritability estimates suggest a genetic contribution, no previous study has conclusively identified a genetic risk variant for mathematical performance. Research has shown that the prevalence of mathematical disabilities is increased in children with dyslexia. We therefore correlated genome-wide data of 200 German children with spelling disability, with available quantitative data on mathematic ability. Replication of the top findings in additional dyslexia samples revealed that rs133885 was a genome-wide significant marker for mathematical abilities\((P_{comb}=7.71 x 10^{-10}, n=699)\), with an effect size of 4.87%. This association was also found in a sample from the general population (P=0.048, n=1080), albeit with a lower effect size. The identified variant encodes an amino-acid substitution in MYO18B, a protein with as yet unknown functions in the brain. As areas of the parietal cortex, in particular the intraparietal sulcus (IPS), are involved in numerical processing in humans, we investigated whether rs133885 was associated with IPS morphology using structural magnetic resonance imaging data from 79 neuropsychiatrically healthy adults. Carriers of the MYO18B risk-genotype displayed a significantly lower depth of the right IPS. This validates the identified association between rs133885 and mathematical disability at the level of a specific intermediate phenotype.
Although sleep problems are common in children with ADHD, their extent, preceding risk factors, and the association between neurocognitive performance and neurobiological processes in sleep and ADHD, are still largely unknown. We examined sleep variables in school-aged children with ADHD, addressing their intra-individual variability (IIV) and considering potential precursor symptoms as well as the chronotype. Additionally, in a subgroup of our sample, we investigated associations with neurobehavioral functioning (n = 44). A total of 57 children (6–12 years) with (n = 24) and without ADHD (n = 33) were recruited in one center of the large ESCAlife study to wear actigraphs for two weeks. Actigraphy-derived dependent variables, including IIV, were analyzed using linear mixed models in order to find differences between the groups. A stepwise regression model was used to investigate neuropsychological function. Overall, children with ADHD showed longer sleep onset latency (SOL), higher IIV in SOL, more movements during sleep, lower sleep efficiency, and a slightly larger sleep deficit on school days compared with free days. No group differences were observed for chronotype or sleep onset time. Sleep problems in infancy predicted later SOL and the total number of movements during sleep in children with and without ADHD. No additional effect of sleep problems, beyond ADHD symptom severity, on neuropsychological functioning was found. This study highlights the importance of screening children with ADHD for current and early childhood sleep disturbances in order to prevent long-term sleep problems and offer individualized treatments. Future studies with larger sample sizes should examine possible biological markers to improve our understanding of the underlying mechanisms.
Human prosociality, encompassing generosity, cooperation, and volunteering, holds a vital role in our daily lives. Over the last decades, the question of whether prosociality undergoes changes over the adult lifespan has gained increased research attention. Earlier studies suggested increased prosociality in older compared to younger individuals. However, recent meta-analyses revealed that this age effect might be heterogeneous and modest. Moreover, the contributing factors and mechanisms behind these age-related variations remain to be identified. To unravel age-related differences in prosociality, the first study of this dissertation employed a meta-analytical approach to summarize existing findings and provide insight into their heterogeneity by exploring linear and quadratic age effects on self-reported and behavioral prosociality. Additionally, two empirical research studies investigated whether these age-related differences in prosociality were observed in real life, assessed through ecological momentary assessment (Study 2), and in a controlled laboratory setting by applying a modified dictator game (Study 3). Throughout these three studies, potential underlying behavioral and computational mechanisms were explored. The outcome of the meta-analysis (Study 1) revealed small linear age effects on prosociality and significant age group differences between younger and older adults, with higher levels of prosociality in older adults. Explorative evidence emerged in favor of a quadratic age effect on behavioral prosociality, indicating the highest levels in midlife. Additionally, heightened prosocial behavior among middle-aged adults was observed compared to younger adults, whereas no significant differences in prosocial behavior were noted between middle-aged and older adults. Situational and contextual features, such as the setting of the study and specific paradigm characteristics, moderated the age-prosociality relationship, highlighting the importance of the (social) context when studying prosociality. For Study 2, no significant age effect on real-life prosocial behavior was observed. However, evidence for a significant linear and quadratic age effect on experiencing empathy in real life emerged, indicating a midlife peak. Additionally, across all age groups, the link between an opportunity to empathize and age significantly predicted real-life prosocial behavior. This effect, indicating higher levels of prosocial behavior when there was a situation possibly evoking empathy, was most pronounced in midlife. Study 3 presented age differences in how older and younger adults integrate values related to monetary gains for self and others to make a potential prosocial decision. Younger individuals effectively combined both values in a multiplicative fashion, enhancing decision-making efficiency. Older adults showed an additive effect of values for self and other and displayed increased decision-making efficiency when considering the values separately. However, among older adults, individuals with better inhibitory control were better able to integrate information about both values in their decisions. Taken together, the findings of this dissertation offer new insights into the multi-faceted nature of prosociality across adulthood and the mechanisms that help explain these age-related disparities. While this dissertation observed increasing prosociality across the adult lifespan, it also questions the assumption that older adults are inherently more prosocial. The studies highlight midlife as a potential peak period in social development but also emphasize the importance of the (social) context and that different operationalizations might capture distinct facets of prosociality. This underpins the need for a comprehensive framework to understand age effects of prosociality better and guide potential interventions.
Tetrahydroisoquinolines (TIQs) such as salsolinol (SAL), norsalsolinol (NSAL) and their methylated derivatives N-methyl-norsalsolinol (NMNSAL) and N-methyl-salsolinol (NMSAL), modulate dopaminergic neurotransmission and metabolism in the central nervous system. Dopaminergic neurotransmission is thought to play an important role in the pathophysiology of chronic tic disorders, such as Tourette syndrome (TS). Therefore, the urinary concentrations of these TIQ derivatives were measured in patients with TS and patients with comorbid attention-deficit/hyperactivity disorder (TS + ADHD) compared with controls. Seventeen patients with TS, 12 with TS and ADHD, and 19 age-matched healthy controls with no medication took part in this study. Free levels of NSAL, NMNSAL, SAL, and NMSAL in urine were measured by a two-phase chromatographic approach. Furthermore, individual TIQ concentrations in TS patients were used in receiver-operating characteristics (ROC) curve analysis to examine the diagnostic value. NSAL concentrations were elevated significantly in TS [434.67 ± 55.4 nmol/l (standard error of mean = S.E.M.), two-way ANOVA, p < 0.0001] and TS + ADHD patients [605.18 ± 170.21 nmol/l (S.E.M.), two-way ANOVA, p < 0.0001] compared with controls [107.02 ± 33.18 nmol/l (S.E.M.), two-way ANOVA, p < 0.0001] and NSAL levels in TS + ADHD patients were elevated significantly in comparison with TS patients (two-way ANOVA, p = 0.017). NSAL demonstrated an AUC of 0.93 ± 0.046 (S.E.M) the highest diagnostic value of all metabolites for the diagnosis of TS. Our results suggest a dopaminergic hyperactivity underlying the pathophysiology of TS and ADHD. In addition, NSAL concentrations in urine may be a potential diagnostic biomarker of TS.
There is no approved drug for fibromyalgia syndrome (FMS) in Europe. In the German S3 guideline, amitriptyline, duloxetine, and pregabalin are recommended for temporary use. The aim of this study was to cross-sectionally investigate the current practice of medication in FMS patients in Germany. We systematically interviewed 156 patients with FMS, while they were participating in a larger study. The patients had been stratified into subgroups with and without a decrease in intraepidermal nerve fiber density. The drugs most commonly used to treat FMS pain were nonsteroidal anti-inflammatory drugs (NSAIDs) (41.0% of all patients), metamizole (22.4%), and amitriptyline (12.8%). The most frequent analgesic treatment regimen was “on demand” (53.9%), during pain attacks, while 35.1% of the drugs were administered daily and the remaining in other regimens. Median pain relief as self-rated by the patients on a numerical rating scale (0–10) was 2 points for NSAIDS, 2 for metamizole, and 1 for amitriptyline. Drugs that were discontinued due to lack of efficacy rather than side effects were acetaminophen, flupirtine, and selective serotonin reuptake inhibitors. Reduction in pain severity was best achieved by NSAIDs and metamizole. Our hypothesis that a decrease in intraepidermal nerve fiber density might represent a neuropathic subtype of FMS, which would be associated with better effectiveness of drugs targeting neuropathic pain, could not be confirmed in this cohort. Many FMS patients take “on-demand” medication that is not in line with current guidelines. More randomized clinical trials are needed to assess drug effects in FMS subgroups.
Background:
Diagnostic guidelines recommend using a variety of methods to assess and diagnose ADHD. Applying subjective measures always incorporates risks such as informant biases or large differences between ratings obtained from diverse sources. Furthermore, it has been demonstrated that ratings and tests seem to assess somewhat different constructs. The use of objective measures might thus yield valuable information for diagnosing ADHD. This study aims at evaluating the role of objective measures when trying to distinguish between individuals with ADHD and controls. Our sample consisted of children (n = 60) and adults (n = 76) diagnosed with ADHD and matched controls who completed self- and observer ratings as well as objective tasks. Diagnosis was primarily based on clinical interviews. A popular pattern recognition approach, support vector machines, was used to predict the diagnosis.
Results:
We observed relatively high accuracy of 79% (adults) and 78% (children) applying solely objective measures. Predicting an ADHD diagnosis using both subjective and objective measures exceeded the accuracy of objective measures for both adults (89.5%) and children (86.7%), with the subjective variables proving to be the most relevant.
Conclusions:
We argue that objective measures are more robust against rater bias and errors inherent in subjective measures and may be more replicable. Considering the high accuracy of objective measures only, we found in our study, we think that they should be incorporated in diagnostic procedures for assessing ADHD.
Die Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung ist eine der häufigsten psychiatrischen Erkrankung des Kindesalters, die eine hohe Heritabilität aufweist und häufig bis ins Erwachsenenalter persistiert und lebenslang zu sozialen, gesundheitlichen und ökonomischen Problemen führt. Die ADHS tritt bei vielen Patienten in Kombina-tion mit anderen psychiatrischen und nicht-psychiatrischen Erkrankungen auf. In den letzten Jahren rückte zunehmend die häufig zur ADHS komorbid auftretende Adipositas in den Fokus der Forschung. Auf der Suche nach copy number variations in Zusammenhang mit ADHS, wurde eine Duplikation auf Chromosom 7p15 – dem Genlocus des NPY – entdeckt. NPY, ist ein endogenes orexigenes Peptid, welches physiologischerweise die Nahrungsaufnahme stimuliert und neben zahlreichen Effekten, wie Blutdruck- und Knochenregulation, auch in Zusammenhang mit neuropsychiatrischen Erkrankungen gebracht werden konnte. Diese Duplikation auf einem Genort, dessen Produkt für die Regulation von Energiehaushalt und Körpergewicht zuständig ist, bildete die Grundlage, eine Assoziationsuntersuchung zu NPY-Genvarianten und dem Körpergewicht bei Kindern durchzuführen.
Untersucht wurden bei 269 an ADHS erkrankten Kindern und 142 gesunden Kontrollkindern die Assoziation zwischen NPY-Genvarianten (rs16147, rs16139, rs5574, rs16124) und ADHS, sowie die Assoziation zwischen NPY-Genvarianten und BMI-Perzentilen bei ADHS.
Es ergab sich keine signifikante Assoziation bezüglich der aufgestellten Hypothesen.
Ziel der Studie war die Exploration von Funktionen des Kurzzeitgedächtnisses bei lese-rechtschreibschwachen Kindern (LRS) im Vergleich zu einer schriftsprachlich normal entwickelten Kontrollgruppe (KG). Gedächtnisfunktionen sollten im Hinblick auf Entwicklungsveränderungen über eine Altersspanne von acht bis dreizehn Jahren untersucht werden. Bei einem möglichen Gedächtnisdefizit sollte überprüft werden, ob dieses sich nur bei schriftsprachähnlichem Material äußerte oder ob es sich um ein allgemeineres Defizit handelte. Insgesamt 65 lese-rechtschreibschwache und schriftsprachlich normal entwickelte Kinder der Altersgruppen 8-9 Jahre, 10-11 Jahre und 12-13 Jahre wurden Aufgaben zur Gedächtnisspanne, zur Benennungsgeschwindigkeit und zur Suchrate unterzogen. In den Aufgaben zur Gedächtnisspanne und zur Benennungsgeschwindigkeit zeigten die lese-rechtschreibschwachen Kinder deutlich schlechtere Leistungen als die Kontrollgruppe, und beide untersuchten Gruppen verbesserten sich in ihren Leistungen mit ansteigendem Alter. Hinweise für ein schriftsprachorientiertes Defizit im Falle der Rechtschreibschwachen ließen sich den Aufgaben zur Gedächtnisspanne und zur Suchrate entnehmen. Zusammenfassend bestätigen die vorliegenden Ergebnisse Defizite in Funktionen des Kurzzeitgedächtnisses bei LRS. Über die untersuchte Altersspanne hinweg kam es nicht zu einer Annäherung der Leistungen der Rechtschreibschwachen an die der Kontrollgruppe, was für ein bleibendes Defizit im Fall der LRS spricht. Um zu eindeutigen Ergebnissen hinsichtlich der Schriftsprachabhängigkeit der Gedächtnisdefizite bei LRS kommen zu können, müssen weitere Studien abgewartet werden.
Background
Current models of Anorexia Nervosa (AN) emphasize the role of emotion regulation. Aversive tension, described as a state of intense arousal and negative valence, is considered to be a link between emotional events and disordered eating. Recent research focused only on adult patients, and mainly general emotion regulation traits were studied. However, the momentary occurrence of aversive tension, particularly in adolescents with AN, has not been previously studied.
Method
20 female adolescents with AN in outpatient treatment and 20 healthy adolescents aged 12 to 19 years participated in an ecological momentary assessment using their smartphones. Current states of aversive tension and events were assessed hourly for two consecutive weekdays. Mean and maximum values of aversive tension were compared. Multilevel analyses were computed to test the influence of time and reported events on aversive tension. The effect of reported events on subsequent changes of aversive tension in patients with AN were additionally tested in a multilevel model.
Results
AN patients showed higher mean and maximum levels of aversive tension. In a multilevel model, reported food intake was associated with higher levels of aversive tension in the AN group, whereas reported school or sport-related events were not linked to specific states of aversive tension. After food intake, subsequent increases of aversive tension were diminished and decreases of aversive tension were induced in adolescents with AN.
Conclusions
Aversive tension may play a substantial role in the psychopathology of AN, particular in relation with food intake. Therefore, treatment should consider aversive tension as a possible intervening variable during refeeding. Our findings encourage further research on aversive tension and its link to disordered eating.
Attention-deficit/hyperactivity disorder (ADHD) is the most prevalent neurodevelopmental disorder described in psychiatry today. ADHD arises during early childhood and is characterized by an age-inappropriate level of inattention, hyperactivity, impulsivity, and partially emotional dysregulation. Besides, substantial psychiatric comorbidity further broadens the symptomatic spectrum. Despite advances in ADHD research by genetic- and imaging studies, the etiopathogenesis of ADHD remains largely unclear. Twin studies suggest a heritability of 70-80 % that, based on genome-wide investigations, is assumed to be polygenic and a mixed composite of small and large, common and rare genetic variants. In recent years the number of genetic risk candidates is continuously increased. However, for most, a biological link to neuropathology and symptomatology of the patient is still missing. Uncovering this link is vital for a better understanding of the disorder, the identification of new treatment targets, and therefore the development of a more targeted and possibly personalized therapy.
The present thesis addresses the issue for the ADHD risk candidates GRM8, FOXP2, and GAD1. By establishing loss of function zebrafish models, using CRISPR/Cas9 derived mutagenesis and antisense oligonucleotides, and studying them for morphological, functional, and behavioral alterations, it provides novel insights into the candidate's contribution to neuropathology and ADHD associated phenotypes. Using locomotor activity as behavioral read-out, the present work identified a genetic and functional implication of Grm8a, Grm8b, Foxp2, and Gad1b in ADHD associated hyperactivity. Further, it provides substantial evidence that the function of Grm8a, Grm8b, Foxp2, and Gad1b in activity regulation involves GABAergic signaling. Preliminary indications suggest that the three candidates interfere with GABAergic signaling in the ventral forebrain/striatum. However, according to present and previous data, via different biological mechanisms such as GABA synthesis, transmitter release regulation, synapse formation and/or transcriptional regulation of synaptic components. Intriguingly, this work further demonstrates that the activity regulating circuit, affected upon Foxp2 and Gad1b loss of function, is involved in the therapeutic effect mechanism of methylphenidate. Altogether, the present thesis identified altered GABAergic signaling in activity regulating circuits in, presumably, the ventral forebrain as neuropathological underpinning of ADHD associated hyperactivity. Further, it demonstrates altered GABAergic signaling as mechanistic link between the genetic disruption of Grm8a, Grm8b, Foxp2, and Gad1b and ADHD symptomatology like hyperactivity. Thus, this thesis highlights GABAergic signaling in activity regulating circuits and, in this context, Grm8a, Grm8b, Foxp2, and Gad1b as exciting targets for future investigations on ADHD etiopathogenesis and the development of novel therapeutic interventions for ADHD related hyperactivity. Additionally, thigmotaxis measurements suggest Grm8a, Grm8b, and Gad1b as interesting candidates for prospective studies on comorbid anxiety in ADHD. Furthermore, expression analysis in foxp2 mutants demonstrates Foxp2 as regulator of ADHD associated gene sets and neurodevelopmental disorder (NDD) overarching genetic and functional networks with possible implications for ADHD polygenicity and comorbidity. Finally, with the characterization of gene expression patterns and the generation and validation of genetic zebrafish models for Grm8a, Grm8b, Foxp2, and Gad1b, the present thesis laid the groundwork for future research efforts, for instance, the identification of the functional circuit(s) and biological mechanism(s) by which Grm8a, Grm8b, Foxp2, and Gad1b loss of function interfere with GABAergic signaling and ultimately induce hyperactivity.
Die ADHS und die Parkinson-Krankheit gehen beide mit Veränderungen des dopaminergen Systems einher. Methylphenidat (MPH) ist ein zentralwirkendes Psychostimulans, das den Dopamin-Wiederaufnahme-Transporter reversibel hemmt. Obwohl MPH seit über 50 Jahren in der symptomatischen Therapie der ADHS angewandt wird, ist die Datenlage zu den Langzeiteffekten und Risiken dieses Medikaments relativ dünn. Basierend auf den Ergebnissen von Versuchen an Ratten wurde die Theorie aufgestellt, dass MPH die Ausreifung des zentralen dopaminergen Systems beeinflusst und dadurch ein Risikofaktor für die Entwicklung eines Parkinson-Syndroms sein könnte.
Ziel dieser Pilotstudie war zum einen zu untersuchen, ob bei Patienten mit Parkinson ADHS-ähnliche Symptome in der Kindheit auftraten und zum anderen zu ermitteln, ob Parkinson-Patienten in ihrer Kindheit Psychostimulanzien eingenommen haben.
Als Instrumentarium dienten die deutsche Kurzform der Wenda Utah Rating Scale (WURS-k) sowie der ‘Fragebogen zu Kindheit und Entwicklung U40‘.
Insgesamt füllten 88 Parkinson-Patienten die Fragebögen vollständig aus. Die Daten dieser Patienten sowie einer ebenso großen, randomisierten Kontrollgruppe wurden in die Auswertung einbezogen.
Im Fragebogen WURS-k fanden sich in der Gruppe der Parkinson-Patienten signifikant höhere Summenscores im Vergleich zur Kontrollgruppe. Zusätzlich zeigten sich bei den Parkinson-Patienten höhere Scores bezüglich der Faktoren „Aufmerksamkeitsdefizit/Hyperaktivität“ sowie „ängstlich-depressive Symptomatik“, nicht aber bei den Faktoren „Impulsivität“, „Protestverhalten“ und „Störung der sozialen Adaptation“. Auch die Auswertung des Fragebogens U40 ergab signifikant höhere Punktwerte bezüglich der Items „Aufmerksamkeitsdefizit“ und „Hyperaktivität“ bei den Parkinson-Patienten.
Dennoch kann aus diesen Ergebnissen nicht geschlossen werden, dass die in unserer Studie untersuchten Parkinson-Patienten in ihrer Kindheit an einer ADHS litten, da die durchschnittlichen Summenscores der WURS-k deutlich unter dem festgelegten Cut-Off-Wert von größer oder gleich 30 lagen. Es ist aber möglich, dass einzelne ADHS-ähnliche Symptome den motorischen Symptomen einer Parkinson-Erkrankung vorausgehen können. Letztlich fanden wir keinen Anhalt dafür, dass die Parkinson-Patienten in ihrer Kindheit Psychostimulanzien wie MPH eingenommen hatten.
Biological Substrates of Waiting Impulsivity in Children and Adolescents with and without ADHD
(2023)
Focus of the present work were the questions whether and how the concept of waiting impulsivity (WI), defined as the ability to regulate a response in anticipation of reward and measured by the 4-choice serial reaction time task (4-CSRTT), may contribute to our understanding of Attention-Deficit/Hyperactivity Disorder (ADHD) and its neurobiological underpinnings.
To address this topic, two studies were conducted: in a first study, the relationship be-tween 4-CSRTT behavioral measures, neural correlates and ADHD symptom domains, i.e. inattention (IA) and hyperactivity/impulsivity (H/I) was explored in a pooled sample of 90 children and adolescents with (n=44) and without (n=46) ADHD diagnosis. As ex-pected, IA was associated with dorsolateral prefrontal brain regions linked with executive functions and attentional control, which was evident on the structural and the functional level. Higher levels of both IA and H/I covaried with decreased activity in the right ven-trolateral prefrontal cortex (PFC), a central structure for response inhibition. Moderation analyses revealed that H/I-related decreased activation in this region did not map linearly on difficulties on the behavioral level: brain activation was a significant predictor of task accuracy only, when H/I symptoms were low/absent but not for clinically relevant ADHD symptoms. Further, H/I was implicated in dysfunctional top-down control of reward eval-uation. Both symptom domains correlated positively with hippocampus (HC) activity in anticipation of reward. In addition, for high H/I symptoms, greater activation in the HC was found to correlate with higher motivation on the behavioral level, indicating that rein-forcement-learning and/or contingency awareness may contribute to altered reward pro-cessing in ADHD patients.
In a second study, the possible serotonergic modulation of WI and the ADHD-WI relation-ship was addressed in a sub-sample comprising 86 children and adolescents of study I. The effects of a functional variant in the gene coding for the rate-limiting enzyme in the synthesis of brain serotonin on behavior and structure or function of the WI-network was investigated. Moderation analyses revealed that on the behavioral level, a negative corre-lation between accuracy and IA was found only in GG-homozygotes, whereas no signifi-cant relationship emerged for carriers of the T-allele. This is in line with previous reports of differential effects of serotonergic modulation on attentional performance depending on the presence of ADHD symptoms. A trend-wise interaction effect of genotype and IA for regional volume of the right middle frontal gyrus was interpreted as a hint towards an involvement of the PFC in this relationship, although a more complex mechanism includ-ing developmental effects can be assumed. In addition, interaction effects of genotype and IA were found for brain activation in the amygdala (AMY) und HC during perfor-mance of the 4-CSRTT, while another interaction was found for H/I symptoms and geno-type for right AMY volume. These findings indicate a serotonergic modulation of coding of the emotional value of reward during performance of the 4-CSRTT that varies de-pending on the extent of psychopathology-associated traits.
Taken together, it was shown that the 4-CSRTT taps distinct domains of impulsivity with relevance to ADHD symptomatology: (proactive) response inhibition difficulties in relation with anticipation of reward. Furthermore, the two symptom domains, IA and H/I, contrib-ute differently to WI, which emphasizes the need to distinguish both in the research of ADHD. The results of study II emphasized the relevance of serotonergic transmission especially for attentional control and emotional processing. Although the present findings need replication and further refinement in more homogenous age groups, the use of the 4-CSRTT with a dimensional approach is a very promising strategy, which will hopefully extend our understanding of impulsivity-related mental disorders in the future.
Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the cornerstone of the development of disease-modifying treatments for Parkinson’s disease (PD). The German Society of Experimental and Clinical Neurotherapeutics (GESENT) has convened a Working Group to review the current status of proposed biomarkers of neurodegeneration according to the following criteria and to develop a consensus statement on biomarker candidates for evaluation of disease-modifying therapeutics in PD. The criteria proposed are that the biomarker should be linked to fundamental features of PD neuropathology and mechanisms underlying neurodegeneration in PD, should be correlated to disease progression assessed by clinical rating scales, should monitor the actual disease status, should be pre-clinically validated, and confirmed by at least two independent studies conducted by qualified investigators with the results published in peer-reviewed journals. To date, available data have not yet revealed one reliable biomarker to detect early neurodegeneration in PD and to detect and monitor effects of drug candidates on the disease process, but some promising biomarker candidates, such as antibodies against neuromelanin, pathological forms of α-synuclein, DJ-1, and patterns of gene expression, metabolomic and protein profiling exist. Almost all of the biomarker candidates were not investigated in relation to effects of treatment, validated in experimental models of PD and confirmed in independent studies.
Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the cornerstone of the development of disease-modifying treatments for Parkinson’s disease (PD). The German Society of Experimental and Clinical Neurotherapeutics (GESENT) has convened a Working Group to review the current status of proposed biomarkers of neurodegeneration according to the following criteria and to develop a consensus statement on biomarker candidates for evaluation of disease-modifying therapeutics in PD. The criteria proposed are that the biomarker should be linked to fundamental features of PD neuropathology and mechanisms underlying neurodegeneration in PD, should be correlated to disease progression assessed by clinical rating scales, should monitor the actual disease status, should be pre-clinically validated, and confirmed by at least two independent studies conducted by qualified investigators with the results published in peer-reviewed journals. To date, available data have not yet revealed one reliable biomarker to detect early neurodegeneration in PD and to detect and monitor effects of drug candidates on the disease process, but some promising biomarker candidates, such as antibodies against neuromelanin, pathological forms of α-synuclein, DJ-1, and patterns of gene expression, metabolomic and protein profiling exist. Almost all of the biomarker candidates were not investigated in relation to effects of treatment, validated in experimental models of PD and confirmed in independent studies.
(1) Background: We aimed to evaluate the effect of proposed “microbiome-stabilising interventions”, i.e., breastfeeding for ≥3 months and prophylactic use of Lactobacillus acidophilus/ Bifidobacterium infantis probiotics on neurocognitive and behavioral outcomes of very-low-birthweight (VLBW) children aged 5–6 years. (2) Methods: We performed a 5-year-follow-up assessment including a strength and difficulties questionnaire (SDQ) and an intelligence quotient (IQ) assessment using the Wechsler Preschool and Primary Scale of Intelligence (WPPSI)-III test in preterm children previously enrolled in the German Neonatal Network (GNN). The analysis was restricted to children exposed to antenatal corticosteroids and postnatal antibiotics. (3) Results: 2467 primary school-aged children fulfilled the inclusion criteria. In multivariable linear regression models breastfeeding ≥3 months was associated with lower conduct disorders (B (95% confidence intervals (CI)): −0.25 (−0.47 to −0.03)) and inattention/hyperactivity (−0.46 (−0.81 to −0.10)) as measured by SDQ. Probiotic treatment during the neonatal period had no effect on SDQ scores or intelligence. (4) Conclusions: Prolonged breastfeeding of highly vulnerable infants may promote their mental health later in childhood, particularly by reducing risk for inattention/hyperactivity and conduct disorders. Future studies need to disentangle the underlying mechanisms during a critical time frame of development.
Catecholaminergic Innervation of Periventricular Neurogenic Regions of the Developing Mouse Brain
(2020)
The major catecholamines—dopamine (DA) and norepinephrine (NE)—are not only involved in synaptic communication but also act as important trophic factors and might ultimately be involved in mammalian brain development. The catecholaminergic innervation of neurogenic regions of the developing brain and its putative relationship to neurogenesis is thus of pivotal interest. We here determined DA and NE innervation around the ventricular/subventricular zone (VZ/SVZ) bordering the whole ventricular system of the developing mouse brain from embryonic day 14.5 (E14.5), E16.5, and E19.5 until postnatal day zero (P0) by histological evaluation and HPLC with electrochemical detection. We correlated these data with the proliferation capacity of the respective regions by quantification of MCM\(^{2+}\) cells. During development, VZ/SVZ catecholamine levels dramatically increased between E16.5 and P0 with DA levels increasing in forebrain VZ/SVZ bordering the lateral ventricles and NE levels raising in midbrain/hindbrain VZ/SVZ bordering the third ventricle, the aqueduct, and the fourth ventricle. Conversely, proliferating MCM\(^{2+}\) cell counts dropped between E16.5 and E19.5 with a special focus on all VZ/SVZs outside the lateral ventricles. We detected an inverse strong negative correlation of the proliferation capacity in the periventricular neurogenic regions (log-transformed MCM\(^{2+}\) cell counts) with their NE levels (r = −0.932; p < 0.001), but not their DA levels (r = 0.440; p = 0.051) suggesting putative inhibitory effects of NE on cell proliferation within the periventricular regions during mouse brain development. Our data provide the first framework for further demandable studies on the functional importance of catecholamines, particularly NE, in regulating neural stem/progenitor cell proliferation and differentiation during mammalian brain development.
Bei der Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörung (ADHS) handelt es sich um ein weltweit verbreitetes Störungsbild mit Beginn in der Kindheit, das sich anhand der Symptome Unaufmerksamkeit, Impulsivität und Hyperaktivität manifestiert. Ein Fortbestehen der Störung in das Jugend- und Erwachsenenalter ist nicht selten. Die Auswirkungen sind dabei vielfältig und führen bei fehlender Behandlung zu psychosozialen Beeinträchtigungen der Betroffenen. Obwohl ADHS mittels multimodaler Therapie behandelbar ist, werden die Diagnose und vor allem die medikamentöse Behandlung weiterhin kontrovers diskutiert. Bei einer zu Grunde liegenden komplexen, multifaktoriellen Genese der Störung ist die Erforschung objektiver Diagnosekriterien, wie es zum Beispiel Biomarker sein könnten, in den Fokus der Forschung gerückt. Für andere neurologische und psychiatrische Erkrankungen, wie zum Beispiel Morbus Parkinson, ist eine Veränderung der Geruchsfunktion bekannt. Auch für die ADHS existieren Studien, die sich mit der Geruchsleistung von Patienten befassen. Eine verbesserte Geruchsensitivität bei Kindern mit ADHS ohne Medikation konnte bereits gezeigt werden. Mit Methylphenidat (MPH) behandelte Patienten zeigten aber keine Verbesserung in der Geruchsleistung. Daher ist es Gegenstand dieser Studie die Geruchsfunktion für die Leistungen Sensitivität (Schwellenwahrnehmung eines Geruchs), Diskrimination (Unterscheidung zweier Gerüche) und Identifikation (Erkennen und Benennen von Gerüchen) bei ADHS- Patienten zu untersuchen, sowie verschiedene Medikationsstatus zu berücksichtigen. Die Geruchsleistung wurde mittels Sniffin´ Sticks, einer klinischen Geruchstestungsbatterie zur Erhebung der genannten Parameter, durchgeführt. Eingeschlossen wurden 112 Kinder zwischen 6 und 12 Jahren mit ADHS sowie 86 Kontrollprobanden zwischen 6 und 12 Jahren. Die Patienten wurden eingeteilt in solche, die noch nie Stimulanzienmedikation erhalten hatten (medikationsnaiv), solche, die aktuell MPH erhielten und solche, die ihre
Medikation zu unterschiedlichen Zeitpunkten abgesetzt hatten (vor maximal 6 Tagen, vor maximal 31 Tagen, vor mehr als 30 Tagen).
Es konnte eine signifikant bessere Sensitivitätsleistung bei Patienten, welche ihre Medikation länger als 30 Tage abgesetzt hatten, im Vergleich zu Kontrollprobanden und allen medizierten Patienten gezeigt werden. Des Weiteren konnte eine verbesserte Sensitivitätsleistung bei ADHS-Patienten, welche ihre Medikation seit einem längeren Zeitraum abgesetzt hatten, im Vergleich zu Kontrollprobanden gefunden werden. Dies ist ein Hinweis für eine mögliche Anpassung der Sensitvitätsleistung an das ursprünglich verbesserte Niveau nach einer gewissen Medikationskarenz.
Bei der ADHS liegt unter anderem eine dopaminerge Dysregulation als krankheitsursächlich zu Grunde. Aufgrund eines erhöhten dopaminergen Tonus beim AHDS in mesolimbischen Bereichen könnte es zu einer verminderten Proliferation von adulten Stammzellen und somit zur Verminderung der Anzahl nachrückender Interneurone, mit daraus resultierender verbesserter Geruchsfunktion bei geringerer dopaminerger Hemmung kommen. Für die Auswirkung der unterschiedlichen Absetzzeiträume auf die Sensitivitätsleistung könnten kurzfristige Mechanismen, wie eine Erhöhung der Durchblutung, und langfristige Mechanismen, die sich durch Veränderungen von Rezeptorprofilen ergeben, bei MPH-Einnahme verantwortlich sein.
Für die Diskriminationsleistung ergab sich in dieser Arbeit eine Verbesserung allein in der medikationsnaiven Patientengruppe, jedoch nur unter Berücksichtigung potentieller Einflussfaktoren wie IQ, Alter und Geschlecht. Daher müssen diese Erkenntnisse mit Vorsicht interpretiert werden.
Auch im Fall der verbesserten Diskriminationsleistung gibt es Hinweise, dass eine veränderte Stammzellproliferation verantwortlich sein könnte.
Bezüglich der Identifikationsleistung ergab sich in der vorliegenden Arbeit eine Verschlechterung der Leistung allein in der Patientengruppe, welche ihre Medikation seit kurzem abgesetzt hatte. Im Gegensatz zur Sensitivität
unterliegen Diskrimination und Identifikation noch weiterer zentraler Prozessierung zum Beispiel im orbitofrontalen Kortex. Die Zusammenhänge sind hier also komplexer. Dennoch unterliegt auch der Hippocampus adulter Neurogenese, so dass Zusammenhänge zwischen dopaminerger Dysregulation und Identifikationsleistung diskutiert werden können.
Die Erkenntnisse der vorliegenden Studie sind ein weiterer Schritt in der Etablierung der Sensitvitätsleistung als Biomarker für ADHS im Kindesalter. Weitere bildgebende Studien könnten die Erkenntnisse erweitern beziehungsweise die genauen Hintergründe bezüglich Diskriminations- und Identifikationsleistung verifizieren. Methodische Unterschiede scheinen für die heterogene Studienlage bezüglich Diskriminations- und Identifikationsleistung verantwortlich.
We aimed to compare the clinical data at first presentation to inpatient treatment of children (<14 years) vs. adolescents (≥14 years) with anorexia nervosa (AN), focusing on duration of illness before hospital admission and body mass index (BMI) at admission and discharge, proven predictors of the outcomes of adolescent AN. Clinical data at first admission and at discharge in 289 inpatients with AN (children: n = 72; adolescents: n = 217) from a German multicenter, web-based registry for consecutively enrolled patients with childhood and adolescent AN were analyzed. Inclusion criteria were a maximum age of 18 years, first inpatient treatment due to AN, and a BMI <10th BMI percentile at admission. Compared to adolescents, children with AN had a shorter duration of illness before admission (median: 6.0 months vs. 8.0 months, p = 0.004) and higher BMI percentiles at admission (median: 0.7 vs. 0.2, p = 0.004) as well as at discharge (median: 19.3 vs. 15.1, p = 0.011). Thus, in our study, children with AN exhibited clinical characteristics that have been associated with better outcomes, including higher admission and discharge BMI percentile. Future studies should examine whether these factors are actually associated with positive long-term outcomes in children.
CNS imaging characteristics in fibromyalgia patients with and without peripheral nerve involvement
(2022)
We tested the hypothesis that reduced skin innervation in fibromyalgia syndrome is associated with specific CNS changes. This prospective case–control study included 43 women diagnosed with fibromyalgia syndrome and 40 healthy controls. We further compared the fibromyalgia subgroups with reduced (n = 21) and normal (n = 22) skin innervation. Brains were analysed for cortical volume, for white matter integrity, and for functional connectivity. Compared to controls, cortical thickness was decreased in regions of the frontal, temporal and parietal cortex in the fibromyalgia group as a whole, and decreased in the bilateral pericalcarine cortices in the fibromyalgia subgroup with reduced skin innervation. Diffusion tensor imaging revealed a significant increase in fractional anisotropy in the corona radiata, the corpus callosum, cingulum and fornix in patients with fibromyalgia compared to healthy controls and decreased FA in parts of the internal capsule and thalamic radiation in the subgroup with reduced skin innervation. Using resting-state fMRI, the fibromyalgia group as a whole showed functional hypoconnectivity between the right midfrontal gyrus and the posterior cerebellum and the right crus cerebellum, respectively. The subgroup with reduced skin innervation showed hyperconnectivity between the inferior frontal gyrus, the angular gyrus and the posterior parietal gyrus. Our results suggest that the subgroup of fibromyalgia patients with pronounced pathology in the peripheral nervous system shows alterations in morphology, structural and functional connectivity also at the level of the encephalon. We propose considering these subgroups when conducting clinical trials.